📊 CRDL Key Takeaways
Is Cardiol Therapeutics Inc. (CRDL) a Good Investment?
Unable to conduct meaningful fundamental analysis due to complete absence of financial data. Company appears to be in pre-revenue or early-stage biotech development phase with no disclosed income statement, balance sheet, or cash flow metrics available in SEC filings.
Cardiol Therapeutics is a pre-revenue, clinical-stage biotech with no operating income, but its balance sheet is relatively clean and its capital raises have meaningfully reduced near-term funding risk. Fundamentals improved modestly in 2025, with the nine-month net loss narrowing to C$26.6M from C$28.5M year over year despite higher R&D spend, but the company remains dependent on clinical execution and external financing rather than self-funded growth.
Why Buy Cardiol Therapeutics Inc. Stock? CRDL Key Strengths
- Operates in biological products sector with potential for high-impact therapeutic development
- Listed on Nasdaq indicating meeting exchange listing standards
- Biotech sector can deliver significant returns if product pipeline succeeds
- Strong liquidity relative to liabilities, with minimal debt and a debt-light capital structure
- Nine-month 2025 net loss and operating cash burn improved modestly versus the prior year while R&D investment increased
- October 2025 financing extended the company's stated cash runway into Q3 2027, supporting late-stage clinical programs
CRDL Stock Risks: Cardiol Therapeutics Inc. Investment Risks
- No revenue generation reported - company is not yet commercially viable
- Complete lack of financial transparency makes risk assessment impossible
- Early-stage biotech companies have extremely high failure rates and cash burn risks
- Unable to assess cash runway, debt levels, or financial sustainability
- No insider buying activity in last 90 days despite early-stage status
- No commercial revenue or gross profit, so profitability remains entirely absent
- Cash burn is still high, with C$18.6M used in operations in the first nine months of 2025
- Growth is financing-supported and share issuance/warrants create ongoing dilution risk if trials run longer or cost more than expected
Key Metrics to Watch
- Revenue and cash flow from clinical trial progress or FDA approvals
- Cash position and burn rate relative to available capital
- Clinical trial outcomes and regulatory milestone achievements
- Balance sheet strength and need for capital raises
- Pipeline advancement and competitive positioning
- Quarterly operating cash burn versus cash and equivalents
- R&D spend efficiency and timing of clinical milestones relative to cash runway
Cardiol Therapeutics Inc. (CRDL) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
CRDL Profit Margin, ROE & Profitability Analysis
CRDL vs Healthcare Sector: How Cardiol Therapeutics Inc. Compares
How Cardiol Therapeutics Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Cardiol Therapeutics Inc. Stock Overvalued? CRDL Valuation Analysis 2026
Based on fundamental analysis, Cardiol Therapeutics Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Cardiol Therapeutics Inc. Balance Sheet: CRDL Debt, Cash & Liquidity
CRDL Revenue Growth, EPS Growth & YoY Performance
CRDL SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Cardiol Therapeutics Inc. (CIK: 0001702123)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Nov 15, 2021 | SC 13G | formsc13g.htm | View → |
❓ Frequently Asked Questions about CRDL
What is the AI rating for CRDL?
Cardiol Therapeutics Inc. (CRDL) has a Combined AI Rating of HOLD from Claude (HOLD) and ChatGPT (HOLD) with 39% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CRDL's key strengths?
Claude: Operates in biological products sector with potential for high-impact therapeutic development. Listed on Nasdaq indicating meeting exchange listing standards. ChatGPT: Strong liquidity relative to liabilities, with minimal debt and a debt-light capital structure. Nine-month 2025 net loss and operating cash burn improved modestly versus the prior year while R&D investment increased.
What are the risks of investing in CRDL?
Claude: No revenue generation reported - company is not yet commercially viable. Complete lack of financial transparency makes risk assessment impossible. ChatGPT: No commercial revenue or gross profit, so profitability remains entirely absent. Cash burn is still high, with C$18.6M used in operations in the first nine months of 2025.
What is CRDL's revenue and growth?
Cardiol Therapeutics Inc. reported revenue of N/A.
Does CRDL pay dividends?
Cardiol Therapeutics Inc. does not currently pay dividends.
Where can I find CRDL SEC filings?
Official SEC filings for Cardiol Therapeutics Inc. (CIK: 0001702123) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CRDL's EPS?
Cardiol Therapeutics Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CRDL a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Cardiol Therapeutics Inc. has a HOLD rating with 39% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CRDL stock overvalued or undervalued?
Valuation metrics for CRDL: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CRDL stock in 2026?
Our dual AI analysis gives Cardiol Therapeutics Inc. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CRDL's free cash flow?
Cardiol Therapeutics Inc.'s operating cash flow is N/A, with capital expenditures of N/A.
How does CRDL compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).